Search research articles
Contact Us
Filters
Showing results (51-60 of 58) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 58 results.
Neurourology and Urodynamics
|
November 7, 2019
Identifying men with global polyuria on a nocturnal-only voiding diary
Thomas F Monaghan, Syed N Rahman, Donald L Bliwise, et al.
Circulation
|
August 30, 2021
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Renato D Lopes, Celestia S Higano, Susan F Slovin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial
Timothy Iveson, Mark P Saunders, Caroline Kelly, et al.
JAMA Surgery
|
June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial
Mikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.
The Lancet. Oncology
|
April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Timothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Health Technology Assessment (Winchester, England)
|
December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
British Journal of Cancer
|
November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
José Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2026
Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial
Ismail Gögenur, Tobias F Justesen, Line S Tarpgaard, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 58) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 58 results.
Neurourology and Urodynamics
|
November 7, 2019
Identifying men with global polyuria on a nocturnal-only voiding diary
Thomas F Monaghan, Syed N Rahman, Donald L Bliwise, et al.
Circulation
|
August 30, 2021
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Renato D Lopes, Celestia S Higano, Susan F Slovin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial
Timothy Iveson, Mark P Saunders, Caroline Kelly, et al.
JAMA Surgery
|
June 12, 2024
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial
Mikail Gögenur, Andreas Weinberger Rosen, Timothy Iveson, et al.
The Lancet. Oncology
|
April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Timothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Health Technology Assessment (Winchester, England)
|
December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
British Journal of Cancer
|
November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
José Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2026
Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial
Ismail Gögenur, Tobias F Justesen, Line S Tarpgaard, et al.
Page
of 6